OncoMatch/Clinical Trials/NCT04520074
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Is NCT04520074 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Etoposide, Cyclophosphamide, Carboplatin/Cisplatin for ovarian cancer.
Treatment: Etoposide, Cyclophosphamide, Carboplatin/Cisplatin — Ovarian cancer was mostly diagnosed at late stage (III/IV) with high rate of recurrence after first line of therapy by optimal cytoreductive sugery and 6cycle of TP chemotherapy. There is no standard maintainance therapy for BRCA1/2 wide-type ovarian cancer. We developed an adjuvant chemotherapy of "three steps" (ACTS). It is adding CTX+VP-16(second step) 6cycle and CTX+CBP(third steps) to firstline chemotherapy (first step). The aim of this study is to verify the effectivity and safety of ACTS in BRCA1/2 wide-type ovarian cancer patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 wild-type
Required: BRCA2 wild-type
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: cytoreductive surgery
optimal cytoreductive surgery with residual tumor ≤ 1cm
Must have received: platinum-based chemotherapy (paclitaxel)
no more than 9 cycle paclitaxel + platinum chemotherapy achieved complete remission
Cannot have received: pelvic or abdominal radiotherapy
Receipt of pelvic or abdominal radiotherapy
Cannot have received: investigational medicinal product
Receipt of any other investigational medicinal product within the last 30 days before randomization
Lab requirements
Blood counts
Hemoglobin ≥9 g/dL; White blood cell count ≥3.0 × 10^9/L; Absolute neutrophil count ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L
Kidney function
Creatinine <1.5 × ULN
Liver function
AST (SGOT)/ALT (SGPT) ≤2.5 ULN; Bilirubin <1.5 × ULN
Adequate bone marrow and hepatic function at Screening: * Hemoglobin ≥9 g/dL * White blood cell count ≥3.0 × 10^9/L * Absolute neutrophil count ≥1.5 × 10^9/L * Platelet count ≥100 × 10^9/L * AST (SGOT)/ALT (SGPT) ≤2.5 ULN * Bilirubin <1.5 × ULN * Creatinine <1.5 × ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify